In a recently published phase 3 trial, the addition of PD-L1 inhibitor pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed higher levels of PD-L1 [26]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.